Stock Analiz

Nanobiotix S.A. (NBTX) financials: revenue, earnings and cash flow

Fiscal 2018–2025 · from SEC filings · data as of November 13, 2026

Summary

Nanobiotix’s revenue went from $4M in fiscal 2018 to $38M in fiscal 2025, growth of about 38.2% a year.

Net income in fiscal 2025 was -$28M, a net margin of -73.5%; the highest of the period.

Free cash flow was -$40M in fiscal 2025 and positive in 0 of the 8 years shown.

Revenue, profit and cash flow by year

Revenue
2018: $4M20182019: $3M20192020: $3M20202021: $3M20212022: $5M20222023: $40M20232024: -$7M20242025: $38M2025$38M
Net income
2018: -$35M20182019: -$57M20192020: -$41M20202021: -$53M20212022: -$61M20222023: -$44M20232024: -$71M20242025: -$28M2025-$28M
Free cash flow
2018: -$30M20182019: -$47M20192020: -$34M20202021: -$34M20212022: -$40M20222023: -$14M20232024: -$21M20242025: -$40M2025-$40M
EPS (diluted)
2018: $-0.6820182019: $-1.1320192020: $-0.8120202021: $-1.0520212022: $-1.2020222023: $-0.8620232024: $-1.3920242025: $-0.552025$-0.55

Income statement

Fiscal year20252024202320222021202020192018
Revenue$38M-$7M$40M$5M$3M$3M$3M$4M
Gross profit————————
Operating income-$13M-$71M-$30M-$50M-$60M-$45M-$53M-$34M
Net income-$28M-$71M-$44M-$61M-$53M-$41M-$57M-$35M
EPS (diluted)$-0.55$-1.39$-0.86$-1.20$-1.05$-0.81$-1.13$-0.68
R&D————————
Revenue growth+612.6%−118.7%+685.4%+69.9%−2.7%+8.0%−28.3%—

Cash flow

Fiscal year20252024202320222021202020192018
Operating cash flow-$39M-$20M-$14M-$40M-$34M-$34M-$46M-$30M
Capital spending-$632153-$878906-$362439-$98127-$258234-$117802-$1M-$476321
Free cash flow-$40M-$21M-$14M-$40M-$34M-$34M-$47M-$30M
Dividends paid$0$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$4M$4M$4M$3M$4M$4M$5M$2M

Balance sheet

Fiscal year20252024202320222021202020192018
Cash$62M$52M$83M$44M$95M$146M$39M$41M
Debt$0$0$0$0$0$0——
Equity-$99M-$68M-$2M-$29M$30M$86M-$2M$16M
Total assets$80M$70M$104M$64M$115M$164M$63M$59M
Shares (diluted)51M51M51M51M51M51M51M51M

Margins and returns

Fiscal year20252024202320222021202020192018
Gross margin————————
Operating margin-33.2%951.1%-74.0%-977.8%-1986.4%-1450.2%-1841.0%-864.2%
Net margin-73.5%947.5%-109.7%-1194.3%-1778.0%-1337.2%-2003.7%-872.2%
FCF margin-104.2%283.6%-35.4%-778.8%-1137.1%-1100.1%-1663.1%-758.9%
ROIC————-155.1%-40.8%—-211.1%
ROE28.4%103.7%2154.1%210.9%-175.7%-47.7%2668.5%-213.1%

Frequently asked questions

What is Nanobiotix’s annual revenue?

$38M in fiscal 2025.

How much profit does Nanobiotix make?

Net income was -$28M in fiscal 2025 (net margin -73.5%).

Is Nanobiotix’s revenue growing?

No: revenue fell 612.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.